natgillin/translations-raw huggingface dataset:
CONBRIZA is only for use in postmenopausal women. 
Zdravilo CONBRIZA je namenjeno le za uporabo pri ženskah v postmenopavzi.
In the osteoporosis treatment study in 7,492 postmenopausal women (mean age, 66 years), among 1,886 subjects treated with bazedoxifene (20 mg), there were 5 cases of ovarian cancer (0.69 per 1,000) and among 1,885 subjects treated with placebo, there were 0 cases of ovarian cancer after 7 years of treatment. 
V študiji zdravljenja osteoporoze pri 7.492 ženskah v postmenopavzi (povprečna starost = 66 let) so po 7 letih zdravljenja med 1.886 osebami, ki so prejemale bazedoksifen (20 mg), ugotovili 5 primerov raka jajčnikov (0,69 na 1.000), med 1.885 osebami, ki so prejemale placebo, pa so ugotovili 0 primerov raka jajčnikov.
There have been post-marketing reports of ocular events other than retinal vein thrombosis. 
V obdobju trženja so poročali o drugih očesnih neželenih učinkih, razen o trombozi ven mrežnice.
In the osteoporosis treatment study in 7,492 postmenopausal women (mean age, 66 years), among 1,886 subjects treated with bazedoxifene (20 mg), there were 5 cases of thyroid cancer (0.69 per 1,000) and among 1,885 subjects treated with placebo, there was 1 case of thyroid cancer (0.14 per 1,000) after 7 years of treatment. 
V študiji zdravljenja osteoporoze pri 7.492 ženskah v postmenopavzi (povprečna starost = 66 let) so po 7 letih zdravljenja med 1.886 osebami, ki so prejemale bazedoksifen (20 mg), ugotovili 5 primerov raka ščitnice (0,69 na 1.000), med 1.885 osebami, ki so prejemale placebo, pa so ugotovili 1 primer raka ščitnice (0,14 na 1.000).
Urticaria, rash, pruritus 
Bolezni kože in podkožja urtikarija, izpuščaj, pruritus
After 7 years the rate per 1,000 women-years was 2.06 in the bazedoxifene 20 mg group and 1.36 in the placebo group (relative risk 1.51). 
Število na 1.000 žensk-let je po 7 letih znašalo 2,06 v skupini, ki je prejemala bazedoksifen v odmerku 20 mg, in 1,36 v skupini, ki je prejemala placebo (relativno tveganje 1,51).
The highest rate of VTE per 1,000 women-years of follow up was observed during the first year: 4.64 in the bazedoxifene 20 mg group and 1.73 in the placebo group (relative risk 2.69).The rate per 1,000 women-years at 3 years was 2.86 in the bazedoxifene 20 mg group and 1.76 in the placebo group (relative risk 1.63). 
Največje število VTE na 1.000 žensk-let so pri spremljanju opažali v prvem letu: 4,64 v skupini, ki je prejemala bazedoksifen v odmerku 20 mg, in 1,73 v skupini, ki je prejemala placebo (relativno tveganje 2,69).
After 7 years of treatment, the rate per 1,000 women-years for ischaemic strokes was the same for the 20 mg bazedoxifene (1.78) and the placebo (1.78) groups. 
Po 7 letih zdravljenja je bilo število ishemičnih kapi na 1.000 žensk-let v skupini, ki je prejemala bazedoksifen v odmerku 20 mg (1,78), enako tistemu v skupini, ki je prejemala placebo (1,78).
MINIMUM PARTICULARS TO APPEAR ON BLISTERS AND STRIPS 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
The apparent oral clearance of bazedoxifene is approximately 4 to 5 l/h/kg. 
Koncentracija v stanju dinamičnega ravnovesja se doseže v drugem tednu jemanja zdravila enkrat na dan. Navidezni peroralni očistek bazedoksifena je približno 4 do 5 l/h/kg.
Retinal vein thrombosis* 
Očesne bolezni tromboza mrežnične vene*
How to store CONBRIZA 
Shranjevanje zdravila CONBRIZA
No dose adjustment is required for mild or moderate renally impaired patients. 
Pri bolnicah z blago do zmerno okvaro ledvic prilagajanje odmerka ni potrebno.
CARTON TEXT 
BESEDILO NA ŠKATLI
Little or no cytochrome P450-mediated metabolism is evident. 
Vidne je komaj kaj ali sploh nič presnove, ki bi jo posredoval citokrom P450.
Vision disorders/Ocular events 
motnje vida/očesni neželeni učinki
Patients with hepatic impairment 
Bolnice z okvaro jeter
Muscle spasms (includes leg cramps) Hot flushes 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva mišični krči (vključno s krči v nogah)
Nervous system disorders 
Bolezni živčevja somnolenca
A single 20 mg dose of bazedoxifene was administered to these subjects. 
Tem bolnicam so dali enkraten 20 mg odmerek bazedoksifena.
A possible risk after short term treatment cannot be excluded. 
Možnega tveganja po kratkotrajnem zdravljenju ni mogoče izključiti.
Tell your doctor if - you are, you think you might be or are planning to become pregnant. 
Povejte svojemu zdravniku, če - ste ali mislite, da bi lahko bili noseči ali če nameravate zanositi.
not known (frequency cannot be estimated from the available data) - increase in liver enzymes 
neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) - povišanje vrednosti jetrnih encimov
Your doctor will check whether Sepioglin is working 3 to 6 months after you start taking it. 
Zdravnik bo preveril, ali zdravilo Sepioglin deluje, 3 do 6 mesecev po tem, ko začnete jemati zdravilo.
If necessary your doctor may tell you to take a different dose. 
Zdravnik vam bo po potrebi morda naročil, da jemljite drugačen odmerek.
Prior to distribution of the prescriber guide in each Member State, the MAH must agree the content and format of the educational material, together with a communication plan, with the national competent authority. 
Pred distribucijo priporočila za v vsaki državi članici, se mora imetnik dovoljenja za promet glede vsebine in oblike izobraževalnega gradiva, vključno z načrtom obveščanja, dogovoriti z nacionalnim pristojnim organom.
Children Use in children under 18 years is not recommended. 
Otroci Uporabe zdravila pri bolnikih, mlajših od 18 let, ne priporočamo.
Patients should be advised to adhere strictly to a caloriecontrolled diet. 
Bolnikom je treba svetovati, da se strogo držijo kalorijsko kontrolirane diete.
14 tablets 28 tablets 30 tablets 50 tablets 56 tablets 90 tablets 98 tablets 
14 tablet 28 tablet 30 tablet 50 tablet 56 tablet 90 tablet 98 tablet
In particular, patients have experienced the following serious side effects: 
Bolniki so zlasti opažali naslednje resne neželene učinke:
Sepioglin helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces. 
Zdravilo Sepioglin pomaga nadzorovati raven sladkorja v krvi, če imate sladkorno bolezen tipa 2, in sicer tako, da telesu pomaga bolje izkoristiti insulin, ki ga izdela.
The safety and efficacy of piogliatazone in children and adolescents under 18 years of age have not been established. 
Varnost in učinkovitost pioglitazona pri otrocih in mladostnikih, mlajših od 18 let, ni potrjena.
A higher number of bone fractures was seen in women (but not in men) taking pioglitazone. 
Opazili so večje število zlomov kosti pri ženskah (vendar ne pri moških), ki so jemale pioglitazon.
WHAT SEPIOGLIN IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO SEPIOGLIN IN ZA KAJ GA UPORABLJAMO
Within each frequency grouping, adverse reactions are presented in order of decreasing incidence and seriousness. 
V vsaki skupini pogostnosti so neželeni učinki navedeni po padajoči pogostnosti in resnosti.
Sepioglin has no or negligible effect on the ability to drive and use machines. 
Zdravilo Sepioglin nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
However, certain medicines are especially likely to affect the amount of sugar in your blood: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) Tell your doctor or pharmacist if you are taking any of these. 
Vendar pa nekatera zdravila še posebej verjetno vplivajo na količino sladkorja v krvi: - gemfibrozil (uporablja se za zniževanje holesterola) - rifampicin (uporablja se za zdravljenje tuberkuloze in drugih okužb) Povejte zdravniku ali farmacevtu, če jemljete katero od teh zdravil.
If you take Sepioglin with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia). 
Če ste vzeli zdravilo Sepioglin z drugimi zdravili za zdravljenje sladkorne bolezni, je bolj verjetno, da vrednost vašega krvnega sladkorja pade pod normalno raven (hipoglikemija).
Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%). 
Po peroralnem dajanju radioaktivno označenega pioglitazona človeku so označevalec zaznali predvsem v blatu (55 %) in manjšo količino v urinu (45 %).
Broken bones 
Zlomljene kosti
You can usually continue to take other medicines whilst you are being treated with Sepioglin. 
Običajno lahko še naprej jemljete druga zdravila, medtem ko se zdravite z zdravilom Sepioglin .
• Caution in use in the elderly in light of age related risks (in particular bladder cancer, fractures and heart failure) 
• Opozorilo o uporabi pri starejših glede na s starostjo povezana tveganja (zlasti za rak mehurja, zlome in srčno popuščanje).
Take Sepioglin daily as prescribed. 
Zdravilo Sepioglin jemljite vsak dan, kakor vam je predpisano.
The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, to be agreed in the Risk Management Plan to be submitted and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP). 
Imetnik dovoljenja za promet z zdravilom bo izvedel farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, dogovorjenem v okviru načrta za obvladovanje tveganja, ki ga mora predložiti, in vseh nadaljnjih posodobitvah RMP v soglasju z Odborom za zdravila za uporabo v humani medicini (CHMP).
- you are breast-feeding or if you are planning to breast-feed your baby. 
- dojite ali če nameravate dojiti svojega otroka.
When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually. 
Pri zdravljenju bolnikov, ki imajo vsaj en dejavnik tveganja za razvoj kongestivnega srčnega popuščanja (npr. predhodni miokardni infarkt ali simptomatsko koronarno arterijsko bolezen ali v primeru starejših bolnikov), bi moral zdravnik začeti zdravljenje z najnižjim možnim odmerkom in ga postopoma višati.
very common (affects more than 1 user in 10) - decreased blood sugar (hypoglycaemia) 
zelo pogosti (pojavijo se pri več kot 1 od 10 bolnikov) - znižanje ravni krvnega sladkorja (hipoglikemija)
The PSUR submission schedule should follow the PSUR submission schedule for the reference medicinal product. 
Predložitev PSUR mora slediti časovnici predložitve PSUR referenčnega zdravila.
What Sepioglin is and what it is used for Before you take Sepioglin How to take Sepioglin Possible side effects 
Kaj je zdravilo Sepioglin in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Sepioglin Kako jemati zdravilo Sepioglin Možni neželeni učinki
The MAH shall submit within 1 month of the Commission decision a Risk Management Plan which will incorporate risk minimisation measures, as detailed below, in line with those required for the reference medicinal product 
Imetnik dovoljenja za promet mora v roku 1 meseca po odločbi Komisije predložiti Načrt za obvladovanje tveganja, ki mora vsebovati ukrepe za zmanjšanje tveganja, ti pa morajo biti v skladu s tistimi, zahtevanimi za referenčno zdravilo.
These effects were independent of pioglitazone's effects on glycaemia and were statistically significant different to glibenclamide. 
Ti učinki niso bili odvisni od učinkov pioglitazona na glikemijo in so se statistično pomembno razlikovali od glibenklamida.
If ALT levels remain > 3 X the upper limit of normal, therapy should be discontinued. 
ostanejo > 3-kratne zgornje meje normalnih vrednosti, je treba zdravljenje prekiniti.
The European Medicines Agency has waived the obligation to submit the results of studies with pioglitazone in all subsets of the paediatric population in Type 2 Diabetes Mellitus. 
Evropska agencija za zdravila je opustila obveznost predložitve rezultatov študij s pioglitazonom pri vseh podskupinah pediatrične populacije z diabetesom tipa 2.
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Sepioglin. 
Če vam je vaš zdravnik povedal, da imate intoleranco za nekatere sladkorje, pokličite svojega zdravnika preden vzamete zdravilo Sepioglin .
2 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials. 
2 O edemih so poročali pri 6-9 % bolnikov, zdravljenih s pioglitazonom leto dni v kontroliranih kliničnih preskušanjih.
Your blood sugar will be checked, and your dose of Sepioglin may need to be changed. 
Preverili bodo raven vašega krvnega sladkorja in vaš odmerek zdravila Sepioglin bo morda potrebno spremeniti.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Sepioglin and insulin experienced the development of heart failure. 
Nekateri bolniki z dolgotrajno sladkorno boleznijo tipa 2 in srčno boleznijo ali predhodno kapjo, ki so bili zdravljeni z zdravilom Sepioglin in insulinom, so doživeli razvoj srčnega popuščanja.
NAME OF THE MARKETING AUTHORISATION HOLDER Vaia S.A. (logo) 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Vaia S.A. (logo)
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group. 
Bolniki, ki so prejemali pioglitazon, so imeli povprečno znižan HbA1c za 0,45 %, v primerjavi s tistimi, ki so nadaljevali zdravljenje samo z insulinom, in znižan odmerek insulina v skupini zdravljeni s pioglitazonom.
Like all medicines, Sepioglin can cause side effects, although not everybody gets them. 
Kot vsa zdravila imajo lahko tudi zdravilo Sepioglin neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Pioglitazone should not be used in patients with hepatic impairment (see section 4.3 and 4.4). 
Pioglitazona pri bolnikih z jetrno okvaro ne smemo uporabljati (glejte poglavji 4.3 in 4.4).
It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus, when metformin is not suitable or has failed to work adequately. 
Je antidiabetično zdravilo za zdravljenje sladkorne bolezni tipa 2 (od insulina neodvisne sladkorne bolezni), ko metformin ni primeren ali ne deluje na ustrezen način.
Important information about some of the ingredients of Sepioglin This medicine contains lactose monohydrate. 
Pomembne informacije o nekaterih sestavinah zdravila Sepioglin To zdravilo vsebuje laktozo monohidrat.
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. 
Izračunana incidenca zlomov je bila 1,9 zlomov na 100 bolniških let pri ženskah, zdravljenih s pioglitazonom in 1,1 zlom na 100 bolniških let pri ženskah, zdravljenih s primerjalnim zdravilom.
Eye disorders visual disturbance1 
Očesne bolezni motnje vida1
Available epidemiological data also suggest a small increased risk of bladder cancer in diabetic patients treated with pioglitazone in particular in patients treated for the longest durations and with the highest cumulative doses. 
Epidemiološki podatki, ki so na voljo, kažejo tudi malo večje tveganje za rak mehurja pri bolnikih s sladkorno boleznijo, zdravljenih s pioglitazonom, zlasti pri bolnikih, ki so zdravljeni najdlje in z najvišjimi kumulativnimi odmerki.
If you have the impression that the effect of Sepioglin is too weak, talk to your doctor. 
Če menite, da je učinek zdravila Sepioglin prešibak, se posvetujte z zdravnikom.
When Sepioglin is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines. 
Če boste jemali zdravilo Sepioglin skupaj z drugimi zdravili za zdravljenje sladkorne bolezni (kot so insulin, klorpropamid, glibenklamid, gliklazid, tolbutamid), vam bo zdravnik povedal, ali morate jemati nižje odmerke teh zdravil.
Before you start taking Sepioglinyou will have a blood sample taken to check your liver function. 
Pred začetkom jemanja zdravila Sepioglin vam bodo odvzeli vzorec krvi, da se preveri delovanje vaših jeter.
If you are following a diabetic diet, you should continue with this while you are taking Sepioglin. 
Če ste na diabetični dieti, jo med jemanjem zdravila Sepioglin nadaljujte.
Environmental Risk Assessment: no environmental impact is anticipated from the clinical use of pioglitazone. 
Ocena tveganja za okolje: ob klinični uporabi pioglitazona ni pričakovati vpliva na okolje.
Therefore, pioglitazone should not be administered to breastfeeding women. 
Zato se pioglitazona doječim ženskam ne sme dajati.
Tell your doctor before you start to take this medicine - if you retain water (fluid retention) or have heart failures problems in particular if you are over 
Bodite posebno pozorni pri uporabi zdravila Sepioglin Preden začnete jemati to zdravilo, seznanite svojega zdravnika - če zadržujete vodo (zastajanje tekočine v telesu) ali imate probleme s srčnim popuščanjem, zlasti če ste starejši od 75 let.
common (affects 1 to 10 users in 100) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence uncommon (affects 1 to 10 users in 1,000) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) - sweating - tiredness - increased appetite 
pogosti (pojavijo se pri 1 do 10 bolnikih od 100 bolnikov) - glavobol - omotica - bolečine v sklepih - impotenca - bolečine v hrbtu - težko dihanje - majhno znižanje števila rdečih krvnih celic - vetrovi občasni (pojavijo se pri 1 do 10 bolnikih od 1.000 bolnikov) - sladkor v urinu, beljakovine v urinu - povišanje vrednosti encimov - občutek vrtenja (vrtoglavica) - potenje - utrujenost - povečan apetit
1 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments. 
1 O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri zdravljenjnu z drugimi hipoglikemiki.
Sepioglin contains pioglitazone. 
Zdravilo Sepioglin vsebuje pioglitazon.
Do not take Sepioglin - if you are hypersensitive (allergic) to pioglitazone or any of the other ingredients of Sepioglin. 
Ne jemljite zdravila Sepioglin - če ste preobčutljivi (alergični) na pioglitazon ali katerokoli sestavino zdravila Sepioglin.
Since there is a potential for an increase in doserelated adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. 
Ker obstaja možnost povečanja od odmerka odvisnih neželenih učinkov, bo morda ob sočasnem dajanju gemfibrozila treba znižati odmerek pioglitazona.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Sepioglin. 
Obstaja povečana možnost zanositve, ker lahko spet pride do ovulacije, ko ste vzeli zdravilo Sepioglin.
If you forget to take Sepioglin 
Če ste pozabili vzeti zdravilo Sepioglin
Taking Sepioglin with food and drink You may take your tablets with or without food. 
Jemanje zdravila Sepioglin skupaj s hrano in pijačo Tablete lahko vzamete s hrano ali brez nje.
1, 28 Octovriou str., Ag. Varvara 123 51 Athens, Greece 
1, 28 Octovriou str., Ag. Varvara 123 51 Athens, Grčija
How to store Sepioglin Further information 
Shranjevanje zdravila Sepioglin Dodatne informacije
The other ingredients are lactose monohydrate, hydroxypropylcellulose, carmellose calcium and magnesium stearate. 
- Pomožne snovi so laktoza monohidrat, hidroksipropilceluloza, kalcijev karmelozat in magnezijev stearat.
Heart failure has been experienced commonly (1 to 10 users in 100) in patients taking pioglitazone in combination with insulin. 
Odpoved srca je bila pogosto (1 do 10 uporabnikov od 100) ugotovljena pri bolnikih, ki so jemali pioglitazon v kombinaciji z insulinom.
Heart failure has been reported rarely with marketing use of pioglitazone, but more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
Pri tržni uporabi pioglitazona so redko poročali o srčnem popuščanju, vendar bolj pogosto, ko so uporabili pioglitazon v kombinaciji z insulinom ali pri bolnikih z anamnezo srčnega popuščanja.
Do not use Sepioglin after the expiry date which is stated on the carton and the blister pack after the word “EXP”. 
Zdravila Sepioglin ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na pretisnem omotu, poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
Pioglitazone will not affect your ability to drive or use machines but take care if you experience abnormal vision. 
Vpliv na sposobnost upravljanja vozil in strojev Pioglitazon ne bo vplival na vašo sposobnost vožnje ali upravljanja strojev, vendar bodite pozorni, če imate motnje vida.
Pharmacovigilance Plan or risk minimisation activities - Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached - At the request of the European Medicines Agency. 
Poleg tega je treba posodobljen RMP predložiti: - po prejemu novih informacij, ki lahko vplivajo na trenutne specifikacije varnosti zdravila, načrt farmakovigilance ali na dejavnosti za zmanjševanje tveganja, - v 60 dneh po doseženem pomembnem mejniku (farmakovigilančnem ali povezanem z zmanjševanjem tveganja) - na zahtevo Evropske agencije za zdravila
In vitro studies have shown no inhibition of any subtype of cytochrome P450. 
Študije in vitro niso pokazale inhibicije kateregakoli podtipa citokroma P450.
If you stop taking Sepioglin 
Če ste prenehali jemati zdravilo Sepioglin
as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. 
kot trojno peroralno zdravljenje v kombinaciji: - z metforminom ali sulfonilsečnino pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) z nezadostnim nadzorom glikemije kljub dvojnemu peroralnemu zdravljenju.
Frequency of adverse reactions of pioglitazone by treatment regimen Combination 
Pogostnost neželenih učinkov pioglitazona glede na režim zdravljenja Kombinacija
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. 
V 20tedenski študiji je pioglitazon znižal raven trigliceridov na tešče, pa tudi hipertrigliceridemijo po obroku prek učinkovanja na absorbirane in v jetrih sintetizirane trigliceride.
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates). 
Skoraj vse osebe (95 %) so prejemale kardiovaskularna zdravila (zaviralce adrenergičnih receptorjev beta , zaviralce ACE , antagoniste angiotenzina II, zaviralce kalcijevih kanalčkov, nitrate, diuretike, acetilsalicilno kislino, statine, fibrate).
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone. 
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3-4 % in hematokrit 3,6-4,1 % relativna znižanja) in v manjšem obsegu pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (hemoglobin 1-2 % in hematokrit 1-3,2 % relativna znižanja).